Takeda establishes new trading company and reinforces business structure in China

TakedaTakeda Pharmaceutical Company Limited ("Takeda") today announced the launch of a new trading company in China, Takeda (China) International Trading Co., Ltd. ("TCIT"), which will strengthen its business structure in China, and is an important step in the local integration of Nycomed following Takeda's acquisition of Nycomed completed in September 2011.

TCIT, which began operations in January 2013, will serve as a central hub for importing Takeda products from the Company's global manufacturing sites. To complete the integration with Nycomed in China, about 500 employees from Nycomed Pharmaceutical Consultancy (Shanghai) Co., Ltd. ("Nycomed Shanghai") are being transferred to TCIT and other Takeda China organizations. The liquidation of Nycomed Shanghai is planned to be completed by the end of March 2015.

"Takeda provides patients across China with a broad portfolio of products, which are adapted to local patient needs. Our new business structure will simplify our distribution processes and improve our efficiency to better serve patients in this huge and important market," said Haruhiko Hirate, Corporate Officer and Head of North Asia of Takeda. "In conjunction with the recent opening of our Development Center in Shanghai, we are now best equipped to bring new products to Chinese patients as early as possible."

China is Takeda's seventh largest market by revenue, and a cornerstone of Takeda's strategy to grow in emerging markets. Takeda entered the Chinese market in 1994, and established a strong footprint in China, which today includes sales and marketing, development and manufacturing. Most recently, the acquisition of Nycomed and the investment in the Takeda Shanghai Development Center further strengthened Takeda's commercial position as well as clinical development capabilities.

China is expected to be the largest market in Asia, and second largest globally by 2016. Takeda is outpacing the market growth in China, with the highest market share among Japanese pharmaceutical companies in the country. The Company aims to achieve top line growth of 29% CAGR between FY 2012-2016.

Further information about Takeda (China) International Trading Co., Ltd.:
This company will import finished products from Takeda global manufacturing sites and transfer them to Takeda Pharmaceutical (China) Company Limited, which is the distribution hub for all Takeda products. The current sales force and marketing team of Nycomed Shanghai now belong to this company. The profile of this company is as follows:

  • Establishment: September 2012 (capital paid in October 2012)
  • Start of operation: January 2013
  • Location: Shanghai Waigaoqiao Free Trade Zone
  • Capital Stock: 8.4 million USD

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]